Mirum Pharmaceuticals ’ Livmarli Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis

FOSTER CITY, Calif.--(BUSINESS WIRE) March 13, 2024 -- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved Livmarli® (maralixibat) oral solution for the treatment of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news